ImmuCell Balance Sheet Health
Financial Health criteria checks 5/6
ImmuCell has a total shareholder equity of $26.4M and total debt of $10.9M, which brings its debt-to-equity ratio to 41.3%. Its total assets and total liabilities are $44.4M and $18.0M respectively.
Key information
41.3%
Debt to equity ratio
US$10.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.81m |
| Equity | US$26.41m |
| Total liabilities | US$18.04m |
| Total assets | US$44.45m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IUL's short term assets ($13.9M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: IUL's short term assets ($13.9M) exceed its long term liabilities ($13.6M).
Debt to Equity History and Analysis
Debt Level: IUL's net debt to equity ratio (26.9%) is considered satisfactory.
Reducing Debt: IUL's debt to equity ratio has increased from 29.9% to 41.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IUL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IUL has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 14.4% each year.